Celcuity Inc. CELC
otherwise provided in this Annual Report, references to the "Company," "we," "us," and "our"
and similar references refer to Celcuity Inc., a Delaware corporation. We own various unregistered trademarks and service marks, including
our corporate logo. Solely for convenience, the trademarks, trade names and service marks in this Annual Report, including those owned
by third parties, may be referred to without the ®,TM or SM symbols, but such references should
Last close
65.25
2026-10-23
Market cap
$3.19B
2026-06-30 share count
52-week range
53.54 - 151.02
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.79
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $145.0M | $104.2M | $60.6M | $35.3M | $25.8M | $7.7M | $6.3M | $6.3M | $5.0M | $3.1M |
| SG&A | $27.2M | $9.1M | $5.6M | $4.1M | $2.6M | $1.9M | $1.5M | $1.6M | $972.5K | $263.7K |
| Total operating expenses | $172.2M | $113.3M | $66.2M | $39.4M | $28.4M | $9.6M | $7.8M | $7.9M | $6.0M | $3.3M |
| Operating income | -$172.2M | -$113.3M | -$66.2M | -$39.4M | -$28.4M | -$9.6M | -$7.8M | -$7.9M | -$6.0M | -$3.3M |
| Interest expense | $17.1M | $10.3M | $5.3M | $2.1M | $1.3M | $120 | $159 | $111 | $451.7K | $0 |
| Pre-tax income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | -$29.6M | -$9.5M | -$7.4M | -$7.5M | -$6.3M | -$3.3M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$177.0M | -$111.8M | -$63.8M | -$40.4M | -$29.6M | -$9.5M | -$7.4M | -$7.5M | -$6.3M | -$3.3M |
| EPS, basic | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 | — | — | — | — | — |
| EPS, diluted | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 | -0.92 | -0.72 | -0.74 | -0.84 | -0.52 |
| Shares, diluted (wtd. avg.) | 46.8M | 39.4M | 23.7M | 15.4M | 13.4M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $165.7M | $22.5M | $30.7M | $24.6M | $84.3M | $11.6M | $18.7M | $15.9M | $2.7M | $5.9M |
| Short-term investments | $275.8M | $212.6M | $149.9M | $144.0M | — | — | $0 | $9.0M | $21.6M | $0 |
| Total current assets | $465.7M | $244.6M | $190.6M | $175.2M | $85.4M | $12.2M | $19.3M | $25.2M | $24.5M | $5.9M |
| Property, plant and equipment | $499.0K | $336.0K | $228.8K | $260.3K | $312.4K | $558.9K | $833.5K | $813.6K | $280.1K | $144.9K |
| Total assets | $466.6M | $245.1M | $191.2M | $175.7M | $85.9M | $13.0M | $20.3M | $26.0M | $32.0M | $6.1M |
| Accounts payable | $6.4M | $9.4M | $5.1M | $2.6M | $1.5M | $217.4K | $142.8K | $119.8K | $71.9K | $331.5K |
| Total current liabilities | $44.2M | $31.7M | $14.2M | $6.9M | $2.5M | $1.2M | $911.3K | $662.3K | $578.1K | $445.4K |
| Long-term debt | $137.5M | $105.1M | $37.6M | $35.8M | $16.0M | — | — | — | — | — |
| Total liabilities | $366.0M | $129.5M | $51.5M | $41.9M | $17.2M | $1.3M | $983.2K | $682.2K | $578.1K | $445.4K |
| Retained earnings | -$448.9M | -$271.9M | -$160.1M | -$96.3M | -$55.9M | -$26.3M | -$16.8M | -$9.5M | -$2.0M | -$8.3M |
| Total equity | $100.6M | $115.6M | $139.8M | $133.8M | $68.7M | $11.7M | $19.3M | $25.3M | $31.4M | $5.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$153.3M | -$83.5M | -$53.8M | -$36.0M | -$20.3M | -$7.1M | -$6.0M | -$6.1M | -$4.9M | -$2.9M |
| Depreciation and amortisation | $167.0K | $130.0K | $142.8K | $210.9K | $303.2K | $385.6K | $339.0K | $223.0K | $104.7K | $73.1K |
| Stock-based compensation | $21.4M | $7.0M | $4.9M | $4.6M | $2.6M | $1.8M | $1.0M | $1.2M | $874.4K | $187.3K |
| Capital expenditure | $249.0K | $250.0K | $97.6K | $158.8K | $81.9K | $89.4K | $380.2K | $629.6K | $239.8K | $40.9K |
| Investing cash flow | -$64.1M | -$63.1M | -$5.0M | -$144.0M | -$81.4K | -$89.4K | $8.5M | $19.1M | -$29.0M | -$40.9K |
| Financing cash flow | $360.6M | $138.4M | $64.9M | $120.3M | $93.0M | $138.0K | $259.3K | $236.7K | $30.7M | $3.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012801.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$3.3M | -$6.3M | -$7.5M | -$7.4M | -$9.5M | -$29.6M | -$40.4M | -$63.8M | -$111.8M | -$177.0M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |